

At page 1, line 7, delete ", under Express Mail Label No. EM432185810US".

At page 20, line 23, after "SEQ ID NOS:" insert --10-86--.

At page 21, line 7, after "SEQ ID NOS:" insert --10-86--.

At page 40, line 26, delete "SEQ ID NO:1" and insert --SEQ ID NOS:1 and 2--.

At page 40, line 30, delete "ID NO:2" and insert --ID NO:3--.

At page 41, line 1, delete "ID NO:3" and insert --ID NO:4--.

At page 58, line 9, after "SEQ ID NOS:" insert --8 and 9--.

At page 58, line 11, after "SEQ ID NOS:" insert --5-7--.

At page 58, line 19, after "SEQ ID NO:" insert --87--.

At page 58, line 21, after "SEQ ID NO:" insert --88--.

At page 58, line 27, after "SEQ ID NOS:" insert --8 and 9--.

At page 59, line 6, delete "(SEQ ID NOS: )".

At page 62, line 11, after "SEQ ID NO:" insert --8--.

Please delete Tables 1-4 in their entirety and replace them with the enclosed Tables 1-4.

#### In the Figures

Please replace Figures 1A-1E with the enclosed Figures 1A-1E.

#### In the Claims

Please amend claim 2 as follows:

2. (amended) A method for [prolonging the residence time] increasing the pharmacokinetic properties of a Nucleic Acid Ligand in an [ocular application] eye comprising [attaching] covalently linking a Non-Immunogenic, High Molecular Weight compound to a Nucleic Acid Ligand to form a complex comprised of a Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound, and administering said complex [directly] to the eye.

Please add the following new claims 3-21.

3. The RNA ligand to VEGF of claim 1 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 1-4 (SEQ ID NOS: 10-86).